Table 1 Baseline information and clinical characteristics of patients and donors
Patients’ characteristics | ||
|---|---|---|
Age [Median range] (year) | 18 [8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43] | |
Gender | Male Female | 42 (78%) 12 (22%) |
ABO compatibility | Compatible Minor inc Major inc | 35 (64.8%) 12 (22.3%) 7 (12.9%) |
HCT-CI | 0–2  ≥ 3 | 33 (62%) 21 (38%) |
Disease risk index (DRI) | Low Intermediate High/very High | 9 (16.6%) 32 (59.2%) 13 (24.2%) |
CMV | Recipient positive Recipient negative | 34 (63%) 20 (37%) |
Graft composition Median | Median CD34 + cells: 10*6 /kg Median CD3 + T cells: 10*7 /kg | 6.5 (4.1–10.8) 22.3 (7.3–50.6) |
Status at treatment | CR1 CR2 | 33 (62%) 21 (38%) |
Donor’s and transplant characteristics | ||
Age [Median range] (year) | 26 [7–61] | |
Gender match | FDMR Other | 11 (20%) 43 (80%) |
CMV serostatus (D/R) |  + / +   − / +   + / −   − / −  | 4 (7.4%) 29 (53.7%) 4 (7.4%) 17 (31.5%) |
Donor relationship | sibling ≥ 16 sibling ≤ 16 Parent | 16 (29.6%) 22 (40.7%) 16 (29.6%) |
HLA × /10 mismatch (GVH) |  ≤ 3 4 5 | 12 (22/2%) 14 (26%) 28 (51/8%) |
Donor KIR haplotype | AA AB BB | 17 (31.4%) 31 (57.4%) 6 (11.2%) |
KIR/HLA mismatch | 0  ≥ 1 | 24 (44.4%) 30 (55.6%) |